Document is current
Any future updates will be listed below
-
Authors
de Lusignan, Simon http://orcid.org/0000-0002-8553-2641
Hinton, William
Konstantara, Emmanouela
Munro, Neil
Whyte, Martin
Mount, Julie
Feher, Michael
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 3 September 2018
Accepted: 22 April 2019
First Online: 3 May 2019
Ethics approval and consent to participate
: We received ethical approval from the Health Research Authority, London - Hampstead Research Ethics Committee (Ref 17/LO/1305). Each participant will be asked for written informed consent prior to conducting the focus groups. Informed consent will also be sought from survey participants, and all data are anonymised.
: Not applicable.
: SdeL holds grants from Eli Lilly and Company, GlaxoSmithKline, Takeda, AstraZeneca, and Novo Nordisk Ltd. through the University of Surrey for investigator lead research in diabetes; WH has had part of his academic salary funded through these awards (Eli Lilly and Company, Novo Nordisk Ltd., and AstraZeneca UK Ltd). EK has nothing to declare. NM has received financial support for research, speaker meetings, and consultancy from MSD, Merck, BMS, AstraZeneca, Pfizer, Novo Nordisk Ltd., and Sanofi-Aventis. MW has received financial support for speaker meetings from AstraZeneca and MSD, and support for research from Eli Lilly and Company and Sanofi-Aventis. MF financial support for research, speaker meetings and consultancy from MSD, Merck, BMS, AstraZeneca, Pfizer, Novo Nordisk Ltd., and Sanofi-Aventis. JM is employed by Eli Lilly and Company and the protocol has undergone internal review.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
